Genentech
A Member of the Roche Group

TECENTRIQ®
atezolizumab INJECTION FOR INTRAVENOUS USE 1200 mg

TECENTRIQ® (atezolizumab) is NOW FDA APPROVED for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.[1]

- **TECENTRIQ is also approved for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following any platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant chemotherapy.**

This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

To learn more, please visit www.TECENTRIQ.com

Codes for Your Reference		
Type	**Code**	**Description**
NDC[1]	**50242-917-01** **50242-0917-01**	Carton containing one 1200 mg/20 mL single-dose vial
Hospital Outpatient HCPCS[2]	**C9483**	Injection, atezolizumab, 10 mg

ICD-10-CM[3]	
Upper Tract Urothelial	
C65.1	Malignant neoplasm of the right renal pelvis
C65.2	Malignant neoplasm of the left renal pelvis
C65.9	Malignant neoplasm of the unspecified renal pelvis
C66.1	Malignant neoplasm of the right ureter
C66.2	Malignant neoplasm of the left ureter
C66.9	Malignant neoplasm of the unspecified ureter

Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantees concerning reimbursement or coverage for any service or item.

ICD-10-CM[3]	
Lower Tract Urothelial	
C67.0	Malignant neoplasm of trigone of bladder
C67.1	Malignant neoplasm of dome of bladder
C67.2	Malignant neoplasm of lateral wall of bladder
C67.3	Malignant neoplasm of anterior wall of bladder
C67.4	Malignant neoplasm of posterior wall of bladder
C67.5	Malignant neoplasm of bladder neck
C67.6	Malignant neoplasm of ureteric orifice
C67.7	Malignant neoplasm of urachus
C67.8	Malignant neoplasm of overlapping sites of bladder
C67.9	Malignant neoplasm of bladder, unspecified
C68.0	Malignant neoplasm of the urethra

Abbreviations: HCPCS, Healthcare Common Procedure Coding System; ICD-10-CM, International Classification of Diseases, 10th revision, Clinical Modification; NDC, National Drug Code.

IMPORTANT SAFETY INFORMATION

Serious and sometimes fatal adverse reactions occurred with TECENTRIQ treatment. Warnings and precautions include immune-related serious adverse reactions, including pneumonitis, hepatitis, colitis, endocrinopathies, and other immune-related adverse events. Other warnings and precautions include infection, infusion-related reactions, and embryo-fetal toxicity.

Please see additional Important Safety Information on following page and in accompanying full Prescribing Information.

DISTRIBUTION AND FULFILLMENT INFORMATION

- TECENTRIQ is available through authorized specialty distributors and wholesalers via the TECENTRIQ distribution network
- For additional network information, please contact Genentech BioOncology® Access Solutions by calling 1-888-249-4918 or by visiting www.genentech-access.com/tecentriq/hcp

PATIENT ACCESS INFORMATION

- Genentech BioOncology Access Solutions offers a full range of access and reimbursement support for your patients and practice to minimize delays in therapy and understand patient coverage and out-of-pocket costs
- For information on distribution and patient access support, please contact Genentech BioOncology Access Solutions for TECENTRIQ by calling 1-888-249-4918 or by visiting www.genentech-access.com/tecentriq/hcp

For additional information, please contact your Genentech representative.

IMPORTANT SAFETY INFORMATION

Serious Adverse Reactions

Please refer to the full Prescribing Information for important dose management information specific to adverse reactions.

- **Immune-related pneumonitis.** Immune-mediated pneumonitis or interstitial lung disease, including fatal cases, occurred. Permanently discontinue TECENTRIQ for Grade 3 or 4 pneumonitis
- **Immune-related hepatitis.** Immune-mediated hepatitis, including a fatal case, and liver test abnormalities occurred. Permanently discontinue TECENTRIQ for Grade 3 or 4 immune-mediated hepatitis
- **Immune-related colitis.** Immune-mediated colitis or diarrhea, including a fatal case of diarrhea-associated renal failure, occurred. Permanently discontinue TECENTRIQ for Grade 4 diarrhea or colitis
- **Immune-related endocrinopathies.** Immune-related thyroid disorders, adrenal insufficiency, hypophysitis, and type 1 diabetes mellitus, including diabetic ketoacidosis, occurred. Permanently discontinue TECENTRIQ for Grade 4 hypophysitis
- **Other immune-related adverse reactions.** Meningoencephalitis, myasthenic syndrome/myasthenia gravis, Guillain-Barré syndrome, ocular inflammatory toxicity, and pancreatitis, including increases in serum amylase and lipase levels, have occurred. Permanently discontinue TECENTRIQ for any Grade of meningitis or encephalitis or any grade of myasthenic syndrome/myasthenia gravis or Guillain-Barré syndrome. Permanently discontinue TECENTRIQ for Grade 4 or any grade of recurrent pancreatitis
- **Infection.** Severe infections, including fatal cases, have occurred. Sepsis, herpes encephalitis, and mycobacterial infection leading to retroperitoneal hemorrhage have been observed
- **Infusion-related reactions.** Severe infusion reactions have occurred. Permanently discontinue TECENTRIQ in patients with Grade 3 or 4 infusion reactions
- **Embryo-fetal toxicity.** TECENTRIQ can cause fetal harm in pregnant women. Advise patients of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TECENTRIQ and for at least 5 months after the last dose
- Advise female patients not to breastfeed while taking TECENTRIQ and for at least 5 months after the last dose

Most Common Adverse Reactions

The most common adverse reactions in cisplatin-ineligible UC (rate ≥20%) were fatigue (52%), decreased appetite (24%), diarrhea (24%), and nausea (22%).

The most common adverse reactions in previously treated UC (rate ≥20%) were fatigue (52%), decreased appetite (26%), nausea (25%), urinary tract infection (22%), pyrexia (21%), and constipation (21%).

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see accompanying full Prescribing Information for additional Important Safety Information.

References: 1. TECENTRIQ [package insert]. South San Francisco, CA: Genentech, Inc; 2017. **2.** CMS Manual System. Pub 100-4. Medicare Claims Processing. https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/Downloads/R3602CP.pdf. Published August 26, 2016. Accessed March 14, 2017. **3.** ICD-10-CM Tabular List of Diseases and Injuries. 2016 Code Tables and Index. Centers for Medicare & Medicaid Services (CMS) website. https://www.cms.gov/Medicare/Coding/ICD10/2016-ICD-10-CM-and-GEMs.html. Updated October 8, 2015. Accessed March 14, 2017.

TECENTRIQ®
atezolizumab INJECTION FOR INTRAVENOUS USE 1200 mg

Genentech
A Member of the Roche Group